{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"MaxCyte, Inc."},"Symbol":{"label":"Symbol","value":"MXCT"},"Address":{"label":"Address","value":"9713 KEY WEST AVENUE,SUITE 400, ROCKVILLE, Maryland, 20878, United States"},"Phone":{"label":"Phone","value":"+1 301 944-1700"},"Industry":{"label":"Industry","value":"Biotechnology: Commercial Physical & Biological Resarch"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies."},"CompanyUrl":{"label":"Company Url","value":"https://www.maxcyte.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"James Brady","title":"SVP-Technical Applications & Customer Support"},{"name":"Jay Gelfman","title":"Senior Vice President-Operations"},{"name":"Maher Masoud","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}